Literature DB >> 19955114

Posterior reversible encephalopathy syndrome: long-term follow-up.

Christian Roth1, Andreas Ferbert.   

Abstract

BACKGROUND: Posterior reversible encephalopathy syndrome (PRES) has been known for more than 10 years. The long-term prognosis of this condition remains unknown. PATIENTS AND METHODS: In 2006, the authors screened retrospectively the medical records of our department between 1993 and 2006 for PRES. The authors identified 13 patients. Since 2006, another 12 patients have been included prospectively. Since then, follow-up has been performed yearly for all patients. They were investigated in the outpatient clinic or, if they declined to attend, were interviewed by telephone.
RESULTS: The authors identified 25 patients with 27 episodes of PRES. Eighty-four per cent of the patients had generalised seizures. Their mean blood pressure was 167/100 mm Hg. Follow-up was performed for all patients over a mean period of 2250 days (range 59-9396; median 1699). Symptoms resolved, on average, after 7.5 days. Restitution of imaging abnormalities could be shown in 72% of cases. All others showed a clear improvement, but without complete restitution, after a mean duration of 41 days. Recurrence of PRES was observed in two patients (8%), 3 years after complete recovery from their first episode.
CONCLUSION: These data show that PRES has a good short-term and long-term prognosis. Recurrence is infrequent, even though trigger factors for PRES were repeatedly experienced by the patients. Resolution of MRI lesions is slower than clinical recovery.

Entities:  

Mesh:

Year:  2009        PMID: 19955114     DOI: 10.1136/jnnp.2009.189647

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  50 in total

1.  Cortical blindness and posterior reversible encephalopathy syndrome in an older patient.

Authors:  Sabrina Ait; Thomas Gilbert; Francois Cotton; Marc Bonnefoy
Journal:  BMJ Case Rep       Date:  2012-05-26

2.  [Acute bilateral loss of vision in posterior reversible encephalopathy syndrome].

Authors:  K S Bonsel; I Oberacher-Velten; K Hufendiek; H Jägle
Journal:  Ophthalmologe       Date:  2013-03       Impact factor: 1.059

3.  PRES-ing for Answers About Long-Term Seizure Risk in Patients With Posterior Reversible Encephalopathy Syndrome.

Authors:  David Spencer
Journal:  Epilepsy Curr       Date:  2015 Nov-Dec       Impact factor: 7.500

4.  Reversible cerebral vasoconstriction syndrome: treatment with combined intra-arterial verapamil infusion and intracranial angioplasty.

Authors:  H Farid; J K Tatum; C Wong; V V Halbach; S W Hetts
Journal:  AJNR Am J Neuroradiol       Date:  2011-01-27       Impact factor: 3.825

Review 5.  Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.

Authors:  Melinda Liu; Yuan Yu M Huang; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

6.  A case of posterior reversible encephalopathy syndrome associated with sepsis.

Authors:  Orlando Garner; Alfredo Iardino; Ana Ramirez
Journal:  BMJ Case Rep       Date:  2018-07-10

Review 7.  Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2017-05       Impact factor: 5.606

Review 8.  [Posterior reversible encephalopathy syndrome].

Authors:  D Staykov; S Schwab
Journal:  Nervenarzt       Date:  2012-08       Impact factor: 1.214

9.  Generalised reversible encephalopathy syndrome: a variant of posterior reversible encephalopathy syndrome (PRES).

Authors:  Julia Kunzmann; Hubert Wolf; Stefan Oberndorfer
Journal:  BMJ Case Rep       Date:  2015-11-26

10.  Posterior reversible encephalopathy syndrome (PRES) in a patient with late postpartum eclampsia.

Authors:  Jharendra P Rijal; Smith Giri; Suvash Dawadi; Khagendra V Dahal
Journal:  BMJ Case Rep       Date:  2014-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.